Pacritinib
Vonjo (pacritinib) is a small molecule pharmaceutical. Pacritinib was first approved as Vonjo on 2022-02-28. It is used to treat primary myelofibrosis in the USA. The pharmaceutical is active against tyrosine-protein kinase JAK2. In addition, it is known to target tyrosine-protein kinase JAK1, receptor-type tyrosine-protein kinase FLT3, and tyrosine-protein kinase JAK3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
Vonjo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pacritinib citrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VONJO | CTI Biopharma | N-208712 RX | 2022-02-28 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vonjo | New Drug Application | 2023-08-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| primary myelofibrosis | — | D055728 | D47.4 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PACRITINIB CITRATE, VONJO, CTI BIOPHARMA CORP | |||
| 2029-02-28 | ODE-397 | ||
| 2027-02-28 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
47 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary myelofibrosis | D055728 | — | D47.4 | 7 | 7 | 3 | — | — | 15 |
| Polycythemia vera | D011087 | — | D45 | 2 | 4 | 3 | — | — | 8 |
| Essential thrombocythemia | D013920 | — | D47.3 | 2 | 3 | 3 | — | — | 7 |
| Thrombocytosis | D013922 | HP_0001894 | D75.83 | 2 | 3 | 3 | — | — | 7 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | 2 | 3 | 3 | — | — | 7 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 5 | 7 | — | — | — | 9 |
| Neoplasms | D009369 | — | C80 | 4 | 5 | — | — | — | 8 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 6 | — | — | — | 7 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 4 | 4 | — | — | — | 6 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 4 | — | — | — | 5 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 4 | 3 | — | — | — | 5 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 4 | 3 | — | — | — | 5 |
| Lymphoma | D008223 | — | C85.9 | 4 | 2 | — | — | — | 5 |
| Preleukemia | D011289 | — | — | 2 | 3 | — | — | — | 4 |
| Myeloid leukemia | D007951 | — | C92 | 2 | 3 | — | — | — | 4 |
Show 24 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Waldenstrom macroglobulinemia | D008258 | HP_0005508 | C88.0 | 1 | — | — | — | — | 1 |
| T-cell lymphoma peripheral | D016411 | — | — | 1 | — | — | — | — | 1 |
| T-cell lymphoma cutaneous | D016410 | — | — | 1 | — | — | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pacritinib |
| INN | pacritinib |
| Description | Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2 |
Identifiers
| PDB | — |
| CAS-ID | 937272-79-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2035187 |
| ChEBI ID | — |
| PubChem CID | 46216796 |
| DrugBank | DB11697 |
| UNII ID | G22N65IL3O (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
JAK3
JAK3
NQO2
NQO2
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,018 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,772 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use